Adaptive Medias, Inc. ADTM
We highlighted ADTM several weeks ago on January 28th, and on that day we witnessed a low of 1.58. Over the course of the following month, the stock would gradually make its way to a high of 3.10 (March 4th). That was quite a substantial run, topping out at an increase of 96%
It took another eight sessions for ADTM to come down off of those highs and find support, which it did at 2.00 last Thursday. Since then it has been registering higher lows, and yesterday reached back to a PPS high of 2.41 (+20%), so we’re going to re-radar the stock and keep watch over it into next week.
Totally Hemp Crazy, Inc. THCZ
Another high-performance stock that we first came across a few months back was THCZ. We found this gem back on December 18th and it made a 38% gain for us that day as it ran from .013-.018, but the fun certainly wasn’t over.
It took about six weeks of essentially trading sideways before THCZ would begin one of the most epic runs we’ve seen from a cannabis related play since the ‘Green Rush’ of early 2014. It culminated in a new high during Wednesday’s session, with shares changing hands for as much as .14. That represents a massive spike from the lows we observed in late December totaling 977%
At this point, we’ll be watching to see where THCZ finds support again, where we’ll be waiting for the possibility of a bounce-play on the subsequent rebound. The company put out a fresh PR this morning as well.
Amarantus Bioscience Holdings, Inc. AMBS
We also want to make note of AMBS as the week draws to a close. We have an extensive history with this play, and we re-flagged it on Monday morning as a “Bottom-Watch” play. The ultimate low would come across the tape at the beginning of yesterday’s session at .05 before AMBS began to bounce back.
It reached its way back to .0595 (+18%) and closed there. Moving forward, we’re going to be looking for AMBS to register higher highs and higher lows off of its bottom. The stock was trading as high as .086 at the beginning of this month, and a return to that area from current levels would spell gains on the order of 40%
SIDE NOTE: Speaking of stocks on bottom-watch, we want to call attention to Ohr Pharmaceuticals, Inc. OHRP. The company announced this morning that it had failed to meet its goals in a Phase II study of its OHR-102 drug, and got absolutely crushed in premarket trading down to a low of 2.68. It has recovered slightly, and we’re going to have an eye on OHRP as the session kicks off. The rebound off of such a downturn could be significant.
RHT, BBRY, OREX, LIVE, VJET